Efficacy and safety of intravenous and oral XXXX for @entity3153 .

@entity1 @entity3988 @entity591 @entity955 @entity3153
The electrophysiologic effects and safety of @entity3988 administered either intravenously or orally were studied in 14 @entity1 with @entity3153 during orthodromic reentrant @entity591 and @entity955 ( @entity955 ). Anterograde and retrograde effective refractory periods of the accessory pathway did not change significantly from baseline during either i.v. or oral administration. Administration by either route prevented induction of sustained reentrant @entity591 in 8 @entity1 . In 6 @entity1 , the reentrant @entity591 was either nonsustained (2 @entity1 ) or sustained at much slower rates than the baseline rates (mean +/- standard deviation, baseline, 290 +/- 41 ms; i.v., 355 +/- 40 ms [p less than 0.001]; and oral, 377 +/- 33 ms [p less than 0.001]). In these @entity1 anterograde atrioventricular conduction was prolonged significantly from the mean baseline value of 163 +/- 36 ms to 212 +/- 35 ms with i.v. administration (p less than 0.005) and 225 +/- 33 ms with oral administration (p less than 0.005). Retrograde conduction via the accessory pathway did not change significantly after administration of @entity3988 . The shortest preexcited RR intervals during @entity955 were significantly reduced during i.v. but not during oral administration: control, 327 +/- 47 ms; i.v., 270 +/- 28 ms (p less than 0.001); and oral, 323 +/- 44 ms (difference not significant). In 5 @entity1 @entity955 was sustained for a mean of 20 minutes after i.v. and for 12 minutes after oral administration (p less than 0.20), compared with a baseline mean value of 0.83 minute.(ABSTRACT TRUNCATED AT 250 WORDS)
